Interdisciplinary training in pharmacological sciences

分子药理学和生理学研究生课程规模较小，但非常多样化 该计划具有强大的课程和活动，以及广泛的指导机制。 该计划的领导是由一组三个完成的MPI与互补 确保对项目进行有效监督的优势和专业知识。请求为4 每年T32插槽;该计划的学生总数为20。该培训计划在 “药理科学跨学科培训”将取代我们目前的NIGMS 药理学T32，2021年6月结束。我们项目的培训重点是基础知识 药理学原理、严谨性和可重复性，以及尖端的定量方法。我们 学员参加许多促进互动、协作和专业的活动， 发展在此，我们提出了一些新的举措，在课程，专业 发展、项目监督和招聘。我们最近开发的一项创新计划 该计划是建立在辉瑞制药公司的暑期实习 这些实习将为我们的学员提供独特的机会，亲身体验 在制药公司的科学环境，并为他们的未来做出明智的决定 careers.我们目前的招生和招聘做法产生了很高的比例， 来自弱势群体和代表性不足群体的学生（在过去5年中，47% 代表性不足的少数民族加上7%的残疾人），这些人100%保留 在过去的15年里，该计划的学生（保留该计划一般是95%）。 学生的职业成果非常出色，52%的学生留在学术界 (25%的教师，27%目前是博士后），通常在顶级机构工作，约25%是科学家， 制药或生物技术公司，其余的在各种科学和 医学相关的职业。因此，我们的计划一直在培养一个高度多样化的学生群体 在不同的科学领域取得成功的人;我们提出的新倡议， T32的应用将进一步加强我们独特的计划，提高培训质量。

The Graduate Program in Molecular Pharmacology & Physiology is a small and very diverse program with a strong set of courses and activities, as well as extensive mentoring mechanisms. Leadership of the program is by a group of three accomplished MPIs with complementary strengths and expertise that guarantee effective oversight of the program. The request is for 4 T32 slots per year; the total number of students in the program is 20. This training program in "Interdisciplinary Training in Pharmacological Sciences" will replace our current NIGMS pharmacology T32, ending in June of 2021. The training in our program focuses on fundamental principles of pharmacology, rigor and reproducibility, and cutting-edge quantitative methods. Our trainees participate in many activities that promote interaction, collaboration and professional development. Here we propose a number of new initiatives in the curriculum, professional development, program oversight and recruitment. A recent innovative initiative we are developing in the program is the establishment of summer internships at Pfizer pharmaceutical company labs; these internships will give our trainees the unique opportunity to experience first-hand the scientific environment in a pharmaceutical company and make informed decisions for their future careers. Our current admissions and recruitment practices have yielded a high percentage of students from disadvantaged and underrepresented groups (in the last 5 years, 47% underrepresented minorities plus 7% disabled), and there has been 100% retention of these students in the program during the last 15 years (retention for the program in general is 95%). The career outcomes of the students are excellent, with 52% of students staying in academia (25% faculty, 27% currently postdocs) often at top institutions, about 25% as scientists in pharmaceutical or biotechnology companies, and the remainder in a variety of science and medicine- related careers. Thus, our program has been training a highly diverse group of students who have become successful in different areas of science; the new initiatives proposed in our T32 application will further enhance our unique program and improve the quality of the training.